The Cancer Letter

Inside information on cancer research and drug development

In Brief

Foundation Medicine gets genomic profiling contract from Veterans Affairs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Foundation Medicine Inc. announced a nationwide contract with the U.S. Department of Veterans Affairs National Precision Oncology Program to provide comprehensive genomic profiling for eligible Veterans with advanced cancer.

The contract covers all of Foundation Medicine’s available tests, including FoundationOne CDx and FoundationOne Liquid for solid tumors, as well as FoundationOne Heme for hematologic malignancies.

“Foundation Medicine is honored to be awarded a contract to provide comprehensive genomic profiling for veterans with advanced cancer,” Cindy Perettie, chief executive officer at Foundation Medicine, said in a statement. “This decision by the VA as well as Medicare’s National Coverage Determination issued in early 2018 mark important steps forward in access to personalized cancer care.”

Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

Harnessing innovation: The next frontier in surgical oncology

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
By Yuman Fong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account